A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Acerand Therapeutics Limited
AstraZeneca
Rondo Therapeutics
Candel Therapeutics, Inc.
Nuvectis Pharma, Inc.
Antelope Surgical Solutions, Inc
NiKang Therapeutics, Inc.
Halda Therapeutics OpCo, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Opna Bio LLC
Wren Laboratories LLC
Taproot Health
Carisma Therapeutics Inc
Nimbus Therapeutics
Cellvax Therapeutics Inc
Pfizer
AO GENERIUM
Adaptimmune
Novartis
Novartis
Dendreon
Novartis
Santa Maria Biotherapeutics
Novartis
Novartis
Celldex Therapeutics
Molecular Insight Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Enzon Pharmaceuticals, Inc.
Abbott